Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.

@article{Wang2005PharmacokineticsOG,
  title={Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.},
  author={Lin-run Wang and Ming-zhu Huang and N. Xu and J. Shentu and J. Liu and J. Cai},
  journal={Journal of Zhejiang University. Science. B},
  year={2005},
  volume={6 5},
  pages={
          446-50
        }
}
To determine the pharmacokinetics of gemcitabine (2',2'-difluorodeoxycytidine) in Chinese non-small-cell lung cancer (NSCLC) patients. Six study subjects were administered gemcitabine at a fixed dose rate of 10 mg/m(2) per min (1200 mg/m(2), two hours infusion), and carboplatin and plasma gemcitabine concentrations were measured by ion-pair reversed-phase high-performance liquid chromatography (HPLC). 3P97 Pharmaceutical Kinetics Software was used for the calculation of pharmacokinetic… Expand
The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer
TLDR
The clinical data in this trial supports the further evaluation the regimen in advanced NSCLC patients, due to its predictable kinetic behavior and less severe toxicity profile than expected. Expand
Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC.
TLDR
A rapid and robust RP-HPLC assay for analysis of gemcitabine in human and animal plasma and serum was developed and validated and could also be applied to estimate dFdU levels in human plasma. Expand
Does saturable formation of gemcitabine triphosphate occur in patients?
TLDR
The results showed that first-order and nonsaturable clearance described intracellular dFdCTP formation at clinically applied doses of gemcitabine. Expand
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging
TLDR
A liposomal formulation of Gemcitabine, GemLip, shows promising antitumoral activity on MIA PaCa-2 cells growing orthotopically in nude mice, and Surprisingly, empty liposomes attenuate the spread of metastases similar to Gem citabine and GemLips. Expand
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD
TLDR
The tumor-penetrating Peptide iRGD can enhance the tumor- penetrating ability and therapeutic efficacy of Gemcitabine in the A549 xenograft in patients with NSCLC. Expand
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer
TLDR
The pharmacology, preclinical and clinical data to support the use of gemcitabine partnered with carboplatin for the treatment of advanced non-small-cell lung cancer is evaluated. Expand
New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations
TLDR
In silico methods and AUCeffect are powerful tools to study relationships between tissue drug concentration and the percentage of cell growth inhibition over time and itraconazole was the most effective in combination with either reference anticancer drugs. Expand
Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice
TLDR
Comprehensive pharmacokinetic and biodistribution insights are brought that may explain the previously observed greater efficacy of SQdFdC nanoassemblies against experimental leukemia. Expand
Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.
TLDR
P-GEM is a promising gemcitabine conjugated polymeric micelle for treating pancreatic cancer because it protects GEM from degradation and provides sustained drug release, resulting in enhanced GEM delivery to the tumor by more than 2.5-fold compared to F-G EM. Expand
Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice.
TLDR
It is demonstrated that PSLs provide an efficient and targeted delivery of gemcitabine and may represent a useful new treatment approach for tumors which overexpress the EGFR. Expand
...
1
2
...

References

SHOWING 1-10 OF 14 REFERENCES
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
  • J. Kroep, G. Giaccone, +8 authors G. Peters
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
The gemcitabine-paclitaxel combination significantly increased ribonucleotide levels, most pronounced for adenosine triphosphate (six- to seven-fold) and the pharmacokinetics and pharmacodynamics were not related to response or survival. Expand
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
TLDR
Gem citabine plasma pharmacokinetic parameters are significantly altered in the presence of paclitaxel, and interpatient and intrapatient variability in gemcitabine pharmacokinetics were not observed when gemcitABine was administered in combination with paclitAXel. Expand
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
TLDR
The recommended dose for phase II clinical trials in solid tumors is 790 mg/m2/wk, and the dose-limiting toxicity was myelosuppression, with thrombocytopenia and anemia quantitatively more important than granulocy topenia. Expand
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
TLDR
The single-agent efficacy of gemcitabine is equivalent to other agents commonly used to treat NSCLC, and hematologic toxicity is modest and unlikely to require hospitalization. Expand
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
TLDR
Gemcitabine is an active new agent in the treatment of NSCLC and warrants further investigation in other malignancies and in combination with other agents. Expand
Preclinical, pharmacologic, and phase I studies of gemcitabine.
TLDR
Phase I trials demonstrate that pharmacokinetics are schedule dependent and that, in general, gemcitabine is well tolerated and dose-limiting toxicities are primarily myelosuppression. Expand
Gemcitabine safety overview.
  • M. Green
  • Medicine
  • Seminars in oncology
  • 1996
TLDR
Gemcitabine appears to be exceptionally well tolerated, with low incidences of the gastrointestinal and hair toxicities normally associated with cytotoxic drugs, but there was a higher incidence than expected of flu-like symptoms and edema, although these were rarely serious. Expand
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
TLDR
The combination of gemcitabine and docetaxel administered on days 1 and 8 every 21 days was feasible and well tolerated in patients with advanced malignancies and demonstrated activity in a variety of solid tumors. Expand
Clinical, toxicological and pharmacological aspects of gemcitabine.
TLDR
The current clinical, toxicological and pharmacological data on gemcitabine is reviewed, which shows activity in a variety of solid tumours and differs greatly in their anti-tumour activities. Expand
Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
TLDR
The ability of mononuclear cells to use dFdC for triphosphate formation is saturable, and a dose rate should be considered that produces maximal nucleotide analogue formation, with increased intensity being achieved by prolonging the duration of infusion. Expand
...
1
2
...